{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:54:21Z","timestamp":1774947261113,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41416-018-0312-6","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T17:54:19Z","timestamp":1541699659000},"page":"1392-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts"],"prefix":"10.1038","volume":"119","author":[{"given":"\u00c1d\u00e1m","family":"P\u00f3ti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Berta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Pipek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory T.","family":"Klus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Csabai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Wilcoxen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Mikule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szallasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-0136","authenticated-orcid":false,"given":"D\u00e1vid","family":"Sz\u00fcts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,14]]},"reference":[{"key":"312_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"312_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"312_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, M. J. Targeting the DNA damage response in cancer. Mol. Cell 60, 547\u2013560 (2015).","journal-title":"Mol. Cell"},{"key":"312_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0425-1","volume":"13","author":"L Livraghi","year":"2015","unstructured":"Livraghi, L. & Garber, J. E. PARP inhibitors in the management of breast cancer: current data and future prospects. Bmc. Med. 13, 188 (2015).","journal-title":"Bmc. Med."},{"key":"312_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","volume":"12","author":"A Sonnenblick","year":"2015","unstructured":"Sonnenblick, A., de Azambuja, E., Azim, H. A. Jr. & Piccart, M. An update on PARP inhibitors\u2014moving to the adjuvant setting. Nat. Rev. Clin. Oncol. 12, 27\u201341 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"312_CR6","doi-asserted-by":"crossref","unstructured":"Ang, Y. L. E. & Tan, D. S. P. Development of PARP inhibitors in gynecological malignancies. Curr. Probl. Cancer\u00a041, 273\u2013286 (2017).","DOI":"10.1016\/j.currproblcancer.2017.02.008"},{"key":"312_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday, T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 5, 387\u2013393 (2011).","journal-title":"Mol. Oncol."},{"key":"312_CR8","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/emboj.2009.206","volume":"28","author":"HE Bryant","year":"2009","unstructured":"Bryant, H. E. et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 28, 2601\u20132615 (2009).","journal-title":"EMBO J."},{"key":"312_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nsmb.2258","volume":"19","author":"A Ray Chaudhuri","year":"2012","unstructured":"Ray Chaudhuri, A. et al. Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat. Struct. Mol. Biol. 19, 417\u2013423 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"312_CR10","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588\u20135599 (2012).","journal-title":"Cancer Res."},{"key":"312_CR11","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1021\/jm901188v","volume":"52","author":"P Jones","year":"2009","unstructured":"Jones, P. et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J. Med. Chem. 52, 7170\u20137185 (2009).","journal-title":"J. Med. Chem."},{"key":"312_CR12","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1073\/pnas.1013715108","volume":"108","author":"AG Patel","year":"2011","unstructured":"Patel, A. G., Sarkaria, J. N. & Kaufmann, S. H. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl Acad. Sci. USA 108, 3406\u20133411 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"312_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","volume":"141","author":"SF Bunting","year":"2010","unstructured":"Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243\u2013254 (2010).","journal-title":"Cell"},{"key":"312_CR14","doi-asserted-by":"publisher","first-page":"e0159341","DOI":"10.1371\/journal.pone.0159341","volume":"11","author":"S Ito","year":"2016","unstructured":"Ito, S., Murphy, C. G., Doubrovina, E., Jasin, M. & Moynahan, M. E. PARP inhibitors in clinical use induce genomic instability in normal human cells. PLoS ONE 11, e0159341 (2016).","journal-title":"PLoS ONE"},{"key":"312_CR15","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0006-291X(80)80009-X","volume":"97","author":"A Oikawa","year":"1980","unstructured":"Oikawa, A., Tohda, H., Kanai, M., Miwa, M. & Sugimura, T. Inhibitors of poly(adenosine diphosphate ribose) polymerase induce sister chromatid exchanges. Biochem. Biophys. Res. Commun. 97, 1311\u20131316 (1980).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"312_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0963-7","volume":"17","author":"B Szikriszt","year":"2016","unstructured":"Szikriszt, B. et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol. 17, 99 (2016).","journal-title":"Genome Biol."},{"key":"312_CR17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/onc.2016.243","volume":"36","author":"J Zamborszky","year":"2017","unstructured":"Zamborszky, J. et al. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene 36, 746\u2013755 (2017).","journal-title":"Oncogene"},{"key":"312_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/978-1-62703-739-6_32","volume":"1105","author":"DM Stults","year":"2014","unstructured":"Stults, D. M., Killen, M. W. & Pierce, A. J. The sister chromatid exchange (SCE) assay. Methods Mol. Biol. 1105, 439\u2013455 (2014).","journal-title":"Methods Mol. Biol."},{"key":"312_CR19","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1038\/nprot.2006.358","volume":"1","author":"HM Padilla-Nash","year":"2006","unstructured":"Padilla-Nash, H. M., Barenboim-Stapleton, L., Difilippantonio, M. J. & Ried, T. Spectral karyotyping analysis of human and mouse chromosomes. Nat. Protoc. 1, 3129\u20133142 (2006).","journal-title":"Nat. Protoc."},{"key":"312_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-017-1492-4","volume":"18","author":"O Pipek","year":"2017","unstructured":"Pipek, O. et al. Fast and accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMut. BMC Bioinform. 18, 73 (2017).","journal-title":"BMC Bioinform."},{"key":"312_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nmeth.1628","volume":"8","author":"J Wang","year":"2011","unstructured":"Wang, J. et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat. Methods 8, 652\u2013654 (2011).","journal-title":"Nat. Methods"},{"key":"312_CR22","first-page":"3949","volume":"57","author":"A Umar","year":"1997","unstructured":"Umar, A. et al. Correction of hypermutability, N-methyl-N\u2032-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res. 57, 3949\u20133955 (1997).","journal-title":"Cancer Res."},{"key":"312_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/0008-5472.CAN-05-2853","volume":"66","author":"F Elstrodt","year":"2006","unstructured":"Elstrodt, F. et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 66, 41\u201345 (2006).","journal-title":"Cancer Res."},{"key":"312_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/em.21674","volume":"53","author":"EG Thompson","year":"2012","unstructured":"Thompson, E. G., Fares, H. & Dixon, K. BRCA1 requirement for the fidelity of plasmid DNA double-strand break repair in cultured breast epithelial cells. Environ. Mol. Mutagen. 53, 32\u201343 (2012).","journal-title":"Environ. Mol. Mutagen."},{"key":"312_CR25","doi-asserted-by":"crossref","unstructured":"van Andel, L. et al. Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest. New Drugs 35, 751\u2013765\u00a0(2017).","DOI":"10.1007\/s10637-017-0451-2"},{"key":"312_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"312_CR27","unstructured":"COSMIC. COSMIC: Signatures of Mutational Processes in Human Cancer http:\/\/cancer.sanger.ac.uk\/cosmic\/signatures . Accessed on 5 January 2016."},{"key":"312_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3095","volume":"14","author":"F Reyal","year":"2012","unstructured":"Reyal, F. et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 14, R11 (2012).","journal-title":"Breast Cancer Res."},{"key":"312_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-011-1815-5","volume":"133","author":"P Cottu","year":"2012","unstructured":"Cottu, P. et al. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res. Treat. 133, 595\u2013606 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"312_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.1260825","volume":"347","author":"C Tomasetti","year":"2015","unstructured":"Tomasetti, C. & Vogelstein, B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78\u201381 (2015).","journal-title":"Science"},{"issue":"Suppl. 6","key":"312_CR31","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl. 6), vi24\u2013vi32 (2013).","journal-title":"Ann. Oncol."},{"key":"312_CR32","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","volume":"3","author":"T Higuchi","year":"2015","unstructured":"Higuchi, T. et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol. Res. 3, 1257\u20131268 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"312_CR33","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao, S. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res. 23, 3711\u20133720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"312_CR34","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1038\/sj.onc.1210156","volume":"26","author":"WM Tong","year":"2007","unstructured":"Tong, W. M. et al. Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene 26, 3857\u20133867 (2007).","journal-title":"Oncogene"},{"key":"312_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","volume":"3","author":"JE Jaspers","year":"2013","unstructured":"Jaspers, J. E. et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3, 68\u201381 (2013).","journal-title":"Cancer Discov."},{"key":"312_CR36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature14328","volume":"521","author":"G Xu","year":"2015","unstructured":"Xu, G. et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 521, 541\u2013544 (2015).","journal-title":"Nature"},{"key":"312_CR37","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","volume":"68","author":"EM Swisher","year":"2008","unstructured":"Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581\u20132586 (2008).","journal-title":"Cancer Res."},{"key":"312_CR38","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","volume":"69","author":"W Sakai","year":"2009","unstructured":"Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69, 6381\u20136386 (2009).","journal-title":"Cancer Res."},{"key":"312_CR39","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai, W. et al. Secondary mutatio ns as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116\u20131120 (2008).","journal-title":"Nature"},{"key":"312_CR40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","volume":"7","author":"O Kondrashova","year":"2017","unstructured":"Kondrashova, O. et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 7, 984\u2013998 (2017).","journal-title":"Cancer Discov."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0312-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:39Z","timestamp":1684616619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0312-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["312"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0312-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"10 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was partially funded by Tesaro. Y.X., K.W. and K.M. hold Tesaro stock. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authorisation to use animals in the CERFE facilities was obtained by The Direction des Services V\u00e9t\u00e9rinaires, Minist\u00e8re de l\u2019Agriculture et de la P\u00eache, France (agreement No. B-91-228-107).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"PARP inhibitors are in use for the treatment of ovarian and breast cancer, and are undergoing trials on further cancer types. Due to their relatively mild side effects, PARP inhibitors have the potential for use in long-term maintenance treatment. However, inhibition of DNA repair with this family of drugs could potentially increase genomic mutagenesis, and the treatment-induced mutations could contribute to the development of resistance in the tumour or cause secondary malignancies in somatic cells. In this study, we used a combination of in vitro and in vivo approaches to show that long-term treatment with the PARP inhibitor niraparib has at most a minor mutagenic effect. In contrast to strongly mutagenic treatment with cisplatin, PARP inhibitors, therefore, represent a safer alternative for patients with good prognosis, and our results should increase the confidence in using PARP inhibitors for long-term treatments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Translational Relevance"}}]}}